Cisplatin-based Liposomal Nanocarriers for Drug Delivery in Lung Cancer
Therapy: Recent Progress and Future Outlooks

Kave      Mohammad-Jafari; Seyed   Morteza   Naghib; M.R.      Mozafari
doi:10.2174/0113816128304923240704113319
Note! Please note that this article is currently in the "Article in Press" stage and is not the final "Version of record". While it has been accepted, copy-edited, and formatted, however, it is still undergoing proofreading and corrections by the authors. Therefore, the text may still change before the final publication. Although "Articles in Press" may not have all bibliographic details available, the DOI and the year of online publication can still be used to cite them. The article title, DOI, publication year, and author(s) should all be included in the citation format. Once the final "Version of record" becomes available the "Article in Press" will be replaced by that.
Abstract

In order to improve the treatment of lung cancer, this paper looks at the development of cisplatinbased liposomal nanocarriers. It focuses on addressing the drawbacks of conventional cisplatin therapy, including systemic toxicity, inadequate tumor targeting, and drug resistance. Liposomes, or spherical lipid vesicles, offer a potentially effective way to encapsulate cisplatin, enhancing its transport and minimizing harmful effects on healthy tissues. The article discusses many liposomal cisplatin formulations, including pH-sensitive liposomes, sterically stabilized liposomes, and liposomes coupled with specific ligands like EGFR antibodies. These novel formulations show promise in reducing cisplatin resistance, optimizing pharmacokinetics, and boosting therapeutic results in the two in vitro and in vivo models. They also take advantage of the Enhanced Permeability and Retention (EPR) effect in the direction of improved tumor accumulation. The study highlights the need for more investigation to move these liposomal formulations from experimental to clinical settings, highlighting their potential to offer less harmful and more effective cancer therapy alternatives.
[1]
Arrigoni R, Ballini A, Santacroce L, et al. Another look at dietary polyphenols: Challenges in cancer prevention and treatment. Curr Med Chem  2022; 29(6): 1061-82.
 [http://dx.doi.org/10.2174/1875533XMTE3kMjUp2] [PMID:  34375181]

[2]
Ozkan E, Bakar-Ates F. Ferroptosis: A trusted ally in combating drug resistance in cancer. Curr Med Chem  2022; 29(1): 41-55.
 [http://dx.doi.org/10.2174/0929867328666210810115812] [PMID:  34375173]

[3]
Sahoo BM, Banik BK, Borah P, Jain A. Reactive oxygen species (ROS): Key components in cancer therapies. Anticancer Agents Med Chem  2022; 22(2): 215-22.

[4]
Ullah A, Ullah N, Nawaz T, Aziz T. Molecular mechanisms of Sanguinarine in cancer prevention and treatment. Anticancer Agents Med Chem  2023; 23(7): 765-78.

[5]
Fatima M, Iqubal MK, Iqubal A, et al. Current insight into the therapeutic potential of phytocompounds and their nanoparticle-based systems for effective management of lung cancer. Anticancer Agents Med Chem  2022; 22(4): 668-86.

[6]
Fatima N, Ashique S, Upadhyay A, et al. Current landscape of therapeutics for the management of hypertension: A review. Curr Drug Deliv  2024; 21(5): 662-82.
 [http://dx.doi.org/10.2174/1567201820666230623121433] [PMID:  37357524]

[7]
Ao C, Gao L, Yu L. Research progress in predicting DNA methylation modifications and the relation with human diseases. Curr Med Chem  2022; 29(5): 822-36.
 [http://dx.doi.org/10.2174/0929867328666210917115733] [PMID:  34533438]

[8]
Pohanka M. New uses of melatonin as a drug; A review. Curr Med Chem  2022; 29(20): 3622-37.
 [http://dx.doi.org/10.2174/0929867329666220105115755] [PMID:  34986763]

[9]
Rostán S, Mahler G, Otero L. Selenosemicarbazone metal complexes as potential metal-based drugs. Curr Med Chem  2023; 30(5): 558-72.
 [http://dx.doi.org/10.2174/0929867329666211222115035] [PMID:  34951353]

[10]
Raza F, Siyu L, Zafar H, et al. Recent advances in gelatin-based nanomedicine for targeted delivery of anti-cancer drugs. Curr Pharm Des  2022; 28(5): 380-94.
 [http://dx.doi.org/10.2174/1381612827666211102100118] [PMID:  34727851]

[11]
Garshasbi HR, Naghib SM. Smart stimuli-responsive alginate nanogels for drug delivery systems and cancer therapy: A review. Curr Pharm Des  2023; 29(44): 3546-62.
 [http://dx.doi.org/10.2174/0113816128283806231211073031] [PMID:  38115614]

[12]
Santegoets S, Welters M, van der Burg S. Monitoring of the immune dysfunction in cancer patients. Vaccines  2016; 4(3): 29.
 [http://dx.doi.org/10.3390/vaccines4030029] [PMID:  27598210]

[13]
Alshahrani MY, Alkhathami AG, Almoyad MAA, et al. Phytochemicals as potential inhibitors of interleukin-8 for anticancer therapy: In silico evaluation and molecular dynamics analysis. J Biomol Struct Dyn  2023; 2023: 1-12.
 [http://dx.doi.org/10.1080/07391102.2023.2294387] [PMID:  38116764]

[14]
Singh H, Chopra H, Singh I, et al. Molecular targeted therapies for cutaneous squamous cell carcinoma: Recent developments and clinical implications. EXCLI J  2024; 23: 300-34.
 [PMID:  38655092]

[15]
Salehi S, Naghib SM, Garshasbi HR, Ghorbanzadeh S, Zhang W. Smart stimuli-responsive injectable gels and hydrogels for drug delivery and tissue engineering applications: A review. Front Bioeng Biotechnol  2023; 11: 1104126.
 [http://dx.doi.org/10.3389/fbioe.2023.1104126] [PMID:  36911200]

[16]
Shahidi M, Abazari O, Dayati P, et al. Aptamer-functionalized chitosan-coated gold nanoparticle complex as a suitable targeted drug carrier for improved breast cancer treatment. J Nanotechnol Rev  2022; 11(1): 2875-90.

[17]
Woodman C, Vundu G, George A, Wilson CM. Applications and strategies in nanodiagnosis and nanotherapy in lung cancer, Seminars in cancer biology.  Elsevier 2021; pp. 349-64.

[18]
Unnisa A, Chettupalli AK, Hussain T, Kamal MA. Recent advances in epidermal growth factor receptor inhibitors (EGFRIs) and their role in the treatment of cancer: A review. Anticancer Agents Med Chem  2022; 22(20): 3370-81.

[19]
Mehraj U, Qayoom H, Shafi S, Farhana P, Asdaq S, Mir MA. Cryptolepine targets TOP2A and inhibits tumor cell proliferation in breast cancer cells-an in vitro and in silico study. Anticancer Agents Med Chem  2022; 22(17): 3025-37.

[20]
Shams ul Hassan S, Abbas SQ, Hassan M, Jin H-Z. Computational exploration of anti-cancer potential of guaiane dimers from Xylopia vielana by targeting B-RAF kinase using chemo-informatics, molecular docking, and MD simulation studies. Anticancer Agents Med Chem  2022; 22(4): 731-46.

[21]
Criscitiello C, Guerini-Rocco E, Viale G, et al. Immunotherapy in breast cancer patients: A focus on the use of the currently available biomarkers in oncology. Anticancer Agents Med Chem  2022; 22(4): 787-800.

[22]
Rahmanian M, Sartipzadeh Hematabad O, Askari E, et al. A micropillar array-based microfluidic chip for label-free separation of circulating tumor cells: The best micropillar geometry? J Adv Res  2023; 47: 105-21.
 [http://dx.doi.org/10.1016/j.jare.2022.08.005] [PMID:  35964874]

[23]
Albain KS, Swann RS, Rusch VW, et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: A phase III randomised controlled trial. Lancet  2009; 374(9687): 379-86.
 [http://dx.doi.org/10.1016/S0140-6736(09)60737-6] [PMID:  19632716]

[24]
Timmerman R, Paulus R, Galvin J, et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA  2010; 303(11): 1070-6.
 [http://dx.doi.org/10.1001/jama.2010.261] [PMID:  20233825]

[25]
Bradley J, Thorstad WL, Mutic S, et al. Impact of FDG-PET on radiation therapy volume delineation in non-small-cell lung cancer. Int J Radiat Oncol Biol Phys  2004; 59(1): 78-86.

[26]
Diavati S, Sagris M, Terentes-Printzios D, Vlachopoulos C. Anticoagulation treatment in venous thromboembolism: Options and optimal duration. Curr Pharm Des  2022; 28(4): 296-305.
 [http://dx.doi.org/10.2174/1381612827666211111150705] [PMID:  34766887]

[27]
Waheed A, Zameer S, Ashrafi K, et al. Insights into pharmacological potential of apigenin through various pathways on a nanoplatform in multitude of diseases. Curr Pharm Des  2023; 29(17): 1326-40.
 [http://dx.doi.org/10.2174/1381612829666230529164321] [PMID:  37254541]

[28]
Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med  2016; 375(19): 1823-33.
 [http://dx.doi.org/10.1056/NEJMoa1606774] [PMID:  27718847]

[29]
Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med  2015; 373(2): 123-35.
 [http://dx.doi.org/10.1056/NEJMoa1504627] [PMID:  26028407]

[30]
Ye M, Zhang J, Zhang J, Miao Q, Yao L, Zhang J. Curcumin promotes apoptosis by activating the p53-miR-192-5p/215-XIAP pathway in non-small cell lung cancer. Cancer Lett  2015; 357(1): 196-205.
 [http://dx.doi.org/10.1016/j.canlet.2014.11.028] [PMID:  25444916]

[31]
Roointan A, Sharifi-Rad M, Badrzadeh F, Sharifi-Rad J. A comparison between PLGA-PEG and NIPAAm-MAA nanocarriers in curcumin delivery for hTERT silencing in lung cancer cell line. Cell Mol Biol  2016; 62(9): 51-6.
 [PMID:  27585262]

[32]
Werner ME, Cummings ND, Sethi M, et al. Preclinical evaluation of Genexol-PM, a nanoparticle formulation of paclitaxel, as a novel radiosensitizer for the treatment of non-small cell lung cancer. Int J Radiat Oncol Biol Phys  2013; 86(3): 463-8.

[33]
Ferlay J, Colombet M, Soerjomataram I, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer  2019; 144(8): 1941-53.
 [http://dx.doi.org/10.1002/ijc.31937] [PMID:  30350310]

[34]
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin  2021; 71(3): 209-49.
 [http://dx.doi.org/10.3322/caac.21660] [PMID:  33538338]

[35]
Oudkerk M, Liu S, Heuvelmans MA, Walter JE, Field JK. Lung cancer LDCT screening and mortality reduction evidence, pitfalls and future perspectives. Nat Rev Clin Oncol  2021; 18(3): 135-51.
 [http://dx.doi.org/10.1038/s41571-020-00432-6] [PMID:  33046839]

[36]
Norouzi M, Hardy P. Clinical applications of nanomedicines in lung cancer treatment. Acta Biomater  2021; 121: 134-42.
 [http://dx.doi.org/10.1016/j.actbio.2020.12.009] [PMID:  33301981]

[37]
Wu Y, Zhang J, Zhao J, Wang B. Folate-modified liposomes mediate the co-delivery of cisplatin with miR-219a-5p for the targeted treatment of cisplatin-resistant lung cancer. BMC Pulm Med  2024; 24(1): 159.
 [http://dx.doi.org/10.1186/s12890-024-02938-6] [PMID:  38561695]

[38]
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin  2011; 61(2): 69-90.
 [http://dx.doi.org/10.3322/caac.20107] [PMID:  21296855]

[39]
Ramalingam SS, Owonikoko TK, Khuri FR. Lung cancer: New biological insights and recent therapeutic advances. CA Cancer J Clin  2011; 61(2): 91-112.
 [http://dx.doi.org/10.3322/caac.20102] [PMID:  21303969]

[40]
Ahmad J, Akhter S, Rizwanullah M, et al. Nanotechnology-based inhalation treatments for lung cancer: State of the art. Nanotechnol Sci Appl  2015; 8: 55-66.
 [PMID:  26640374]

[41]
Li QC, Li C, Zhang W, Pi W, Han N. Potential effects of exosomes and their MicroRNA carrier on osteoporosis. Curr Pharm Des  2022; 28(11): 899-909.
 [http://dx.doi.org/10.2174/1381612828666220128104206] [PMID:  35088659]

[42]
Zielińska A, Eder P, Rannier L, et al. Hydrogels for modified-release drug delivery systems. Curr Pharm Des  2022; 28(8): 609-18.
 [http://dx.doi.org/10.2174/1381612828666211230114755] [PMID:  34967292]

[43]
Braunwald E, Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson JL. Harrison’s Principles of Internal Medicine. McGraw-Hill 2001.

[44]
Moss WT, Cox JD. Moss’ radiation oncology: Rationale, technique, results. No Title 1994.

[45]
Steinmaurer A, Wimmer I, Berger T, Rommer PS, Sellner J. Bruton’s tyrosine kinase inhibition in the treatment of preclinical models and multiple sclerosis. Curr Pharm Des  2022; 28(6): 437-44.
 [http://dx.doi.org/10.2174/1381612827666210701152934] [PMID:  34218776]

[46]
Ferlay J, Soerjomataram I, Ervik M. GLOBOCAN 2012 v10 Cancer Incidence and Mortality Worldwide: IARC Cancer Base Number 11. Lyon, France: International Agency for Research on Cancer 2013.

[47]
Ashrafi A, Akter Z, Modareszadeh P, et al. Current landscape of therapeutic resistance in lung cancer and promising strategies to overcome resistance. Cancers  2022; 14(19): 4562.
 [http://dx.doi.org/10.3390/cancers14194562] [PMID:  36230484]

[48]
Lemjabbar-Alaoui H, Hassan OU, Yang Y-W, Buchanan P. Lung cancer: Biology and treatment options. Biochim Biophys Acta  2015; 1856(2): 189-210.

[49]
Zhou J, Huang Q, Huang Z, Li J. Combining immunotherapy and radiotherapy in lung cancer: A promising future? J Thorac Dis  2020; 12(8): 4498-503.
 [http://dx.doi.org/10.21037/JTD-2019-ITM-001] [PMID:  32944363]

[50]
Eberhardt WEE, De Ruysscher D, Weder W, et al. 2nd ESMO consensus conference in lung cancer: Locally advanced stage III non-small-cell lung cancer. Ann Oncol  2015; 26(8): 1573-88.
 [http://dx.doi.org/10.1093/annonc/mdv187] [PMID:  25897013]

[51]
Remon J, Soria JC, Peters S. Early and locally advanced non-small-cell lung cancer: An update of the ESMO Clinical Practice Guidelines focusing on diagnosis, staging, systemic and local therapy. Ann Oncol  2021; 32(12): 1637-42.
 [http://dx.doi.org/10.1016/j.annonc.2021.08.1994] [PMID:  34481037]

[52]
Renault-Mahieux M, Seguin J, Vieillard V, et al. Co-encapsulation of fisetin and cisplatin into liposomes: Stability considerations and in vivo efficacy on lung cancer animal model. Int J Pharm  2024; 651: 123744.
 [http://dx.doi.org/10.1016/j.ijpharm.2023.123744] [PMID:  38145778]

[53]
Zahednezhad F, Zakeri-Milani P, Shahbazi Mojarrad J, Valizadeh H. The latest advances of cisplatin liposomal formulations: Essentials for preparation and analysis. Expert Opin Drug Deliv  2020; 17(4): 523-41.
 [http://dx.doi.org/10.1080/17425247.2020.1737672] [PMID:  32116060]

[54]
Rosenberg B, Van Camp L, Krigas T. Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode. Nature  1965; 205(4972): 698-9.
 [http://dx.doi.org/10.1038/205698a0] [PMID:  14287410]

[55]
Huang Z, Huang Y. The change of intracellular pH is involved in the cisplatin-resistance of human lung adenocarcinoma A549/DDP cells. Cancer Invest  2005; 23(1): 26-32.
 [http://dx.doi.org/10.1081/CNV-46353] [PMID:  15779865]

[56]
Wang D, Lippard SJ. Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov  2005; 4(4): 307-20.
 [http://dx.doi.org/10.1038/nrd1691] [PMID:  15789122]

[57]
Jamieson ER, Lippard SJ. Structure, recognition, and processing of cisplatin DNA adducts. Chem Rev  1999; 99(9): 2467-98.
 [http://dx.doi.org/10.1021/cr980421n] [PMID:  11749487]

[58]
Pavan SR, Prabhu A. Advanced cisplatin nanoformulations as targeted drug delivery platforms for lung carcinoma treatment: A review. J Mater Sci  2022; 57(34): 16192-227.
 [http://dx.doi.org/10.1007/s10853-022-07649-z]

[59]
Chougule M, Patel AR, Sachdeva P, Jackson T, Singh M. Anticancer activity of Noscapine, an opioid alkaloid in combination with Cisplatin in human non-small cell lung cancer. Lung Cancer  2011; 71(3): 271-82.
 [http://dx.doi.org/10.1016/j.lungcan.2010.06.002] [PMID:  20674069]

[60]
Sukumar UK, Bhushan B, Dubey P, Matai I, Sachdev A, Packirisamy G. Emerging applications of nanoparticles for lung cancer diagnosis and therapy. Int Nano Lett  2013; 3(1): 45.
 [http://dx.doi.org/10.1186/2228-5326-3-45]

[61]
Felip E, Stahel RA, Pavlidis N. ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of non-small-cell lung cancer (NSCLC). Ann Oncol  2005; 16 (Suppl. 1): i28-9.
 [http://dx.doi.org/10.1093/annonc/mdi821] [PMID:  15888743]

[62]
Visbal AL, Leighl NB, Feld R, Shepherd FA. Adjuvant chemotherapy for early-stage non-small cell lung cancer. Chest  2005; 128(4): 2933-43.
 [http://dx.doi.org/10.1378/chest.128.4.2933] [PMID:  16236970]

[63]
Johnson BE, Rabin MS. Patient subsets benefiting from adjuvant therapy following surgical resection of non-small cell lung cancer. Clin Cancer Res  2005; 11(13): 5022s-6s.
 [http://dx.doi.org/10.1158/1078-0432.CCR-05-9001] [PMID:  16000607]

[64]
Arriagada R, Dunant A, Pignon JP, et al. Long-term results of the international adjuvant lung cancer trial evaluating adjuvant Cisplatin-based chemotherapy in resected lung cancer. J Clin Oncol  2010; 28(1): 35-42.
 [http://dx.doi.org/10.1200/JCO.2009.23.2272] [PMID:  19933916]

[65]
Hartmann JT, Lipp HP. Toxicity of platinum compounds. Expert Opin Pharmacother  2003; 4(6): 889-901.
 [http://dx.doi.org/10.1517/14656566.4.6.889] [PMID:  12783586]

[66]
Sastry J, Kellie SJ. Severe neurotoxicity, ototoxicity and nephrotoxicity following high-dose cisplatin and amifostine. Pediatr Hematol Oncol  2005; 22(5): 441-5.
 [http://dx.doi.org/10.1080/08880010590964381] [PMID:  16020136]

[67]
Duan X, He C, Kron SJ, Lin W. Nanoparticle formulations of cisplatin for cancer therapy. Wiley Interdiscip Rev Nanomed Nanobiotechnol  2016; 8(5): 776-91.
 [http://dx.doi.org/10.1002/wnan.1390] [PMID:  26848041]

[68]
Mandriota G, Di Corato R, Benedetti M, De Castro F, Fanizzi FP, Rinaldi R. Design and application of cisplatin-loaded magnetic nanoparticle clusters for smart chemotherapy. ACS Appl Mater Interfaces  2019; 11(2): 1864-75.
 [http://dx.doi.org/10.1021/acsami.8b18717] [PMID:  30580523]

[69]
Humes HD. Insights into ototoxicity. Ann N Y Acad Sci  1999; 884(1): 15-8.
 [http://dx.doi.org/10.1111/j.1749-6632.1999.tb00278.x] [PMID:  10842580]

[70]
Arany I, Safirstein RL. Cisplatin nephrotoxicity, Seminars in nephrology.  Elsevier 2003; pp. 460-4.

[71]
Stathopoulos GP, Antoniou D, Dimitroulis J, Stathopoulos J, Marosis K, Michalopoulou P. Comparison of liposomal cisplatin versus cisplatin in non-squamous cell non-small-cell lung cancer. Cancer Chemother Pharmacol  2011; 68(4): 945-50.
 [http://dx.doi.org/10.1007/s00280-011-1572-5] [PMID:  21301848]

[72]
Köberle B, Tomicic MT, Usanova S, Kaina B. Cisplatin resistance: Preclinical findings and clinical implications. Biochim Biophys Acta  2010; 1806(2): 172-82.
 [PMID:  20647037]

[73]
Marrache S, Pathak RK, Dhar S. Detouring of cisplatin to access mitochondrial genome for overcoming resistance. Proc Natl Acad Sci  2014; 111(29): 10444-9.
 [http://dx.doi.org/10.1073/pnas.1405244111] [PMID:  25002500]

[74]
Cleare MJ, Hydes PC, Malerbi BW, Watkins DM. Anti-tumour platinum complexes: Relationships between chemical properties and activity. Biochimie  1978; 60(9): 835-50.
 [http://dx.doi.org/10.1016/S0300-9084(78)80568-9]

[75]
Calvert AH, Newell DR, Gumbrell LA, et al. Carboplatin dosage: Prospective evaluation of a simple formula based on renal function. J Clin Oncol  1989; 7(11): 1748-56.
 [http://dx.doi.org/10.1200/JCO.1989.7.11.1748] [PMID:  2681557]

[76]
Raymond E, Faivre S, Woynarowski JM, Chaney SG. Oxaliplatin: Mechanism of action and antineoplastic activity. Semin Oncol  1998; 25(2)(5): 4-12.
 [PMID: 9609103]

[77]
Amin A, Buratovich M. New platinum and ruthenium complexes the latest class of potential chemotherapeutic drugs: A review of recent developments in the field. Mini Rev Med Chem  2009; 9(13): 1489-503.
 [http://dx.doi.org/10.2174/138955709790361566] [PMID:  20205631]

[78]
Zhou X, Wang J, Wu J, et al. Preparation and evaluation of a novel liposomal formulation of cisplatin. Eur J Pharm Sci  2015; 66: 90-5.
 [http://dx.doi.org/10.1016/j.ejps.2014.10.004] [PMID:  25446511]

[79]
Ghaferi M, Asadollahzadeh MJ, Akbarzadeh A, Ebrahimi Shahmabadi H, Alavi SE. Enhanced efficacy of PEGylated liposomal cisplatin: In vitro and in vivo evaluation. Int J Mol Sci  2020; 21(2): 559.
 [http://dx.doi.org/10.3390/ijms21020559] [PMID:  31952316]

[80]
Alavi SE, Mansouri H, Esfahani MKM, Movahedi F, Akbarzadeh A, Chiani M. Archaeosome: As new drug carrier for delivery of Paclitaxel to breast cancer. Indian J Clin Biochem  2014; 29(2): 150-3.
 [http://dx.doi.org/10.1007/s12291-013-0305-4] [PMID:  24757295]

[81]
Patra JK, Das G, Fraceto LF, et al. Nano based drug delivery systems: Recent developments and future prospects. J Nanobiotechnology  2018; 16(1): 71.
 [http://dx.doi.org/10.1186/s12951-018-0392-8] [PMID:  30231877]

[82]
Iinuma H, Maruyama K, Okinaga K, et al. Intracellular targeting therapy of cisplatin‐encapsulated transferrin‐polyethylene glycol liposome on peritoneal dissemination of gastric cancer. Int J Cancer  2002; 99(1): 130-7.
 [http://dx.doi.org/10.1002/ijc.10242] [PMID:  11948504]

[83]
Ashique S, Upadhyay A, Gulati M, Singh D, Chawla PA, Chawla V. One-dimensional polymeric nanocomposites in drug delivery systems. Curr Nanosci  2023; 19(6): 825-39.
 [http://dx.doi.org/10.2174/1573413719666230110110706]

[84]
Nag S, Mitra O, Tripathi G, et al. Nanomaterials-assisted photothermal therapy for breast cancer: State-of-the-art advances and future perspectives. Photodiagn Photodyn Ther  2024; 45: 103959.
 [http://dx.doi.org/10.1016/j.pdpdt.2023.103959] [PMID:  38228257]

[85]
Gholap AD, Kapare HS, Pagar S, et al. Exploring modified chitosan-based gene delivery technologies for therapeutic advancements. Int J Biol Macromol  2024; 260(Pt 2): 129581.
 [http://dx.doi.org/10.1016/j.ijbiomac.2024.129581] [PMID:  38266848]

[86]
Wu J. The enhanced permeability and retention (EPR) effect: The significance of the concept and methods to enhance its application. J Pers Med  2021; 11(8): 771.
 [http://dx.doi.org/10.3390/jpm11080771] [PMID:  34442415]

[87]
Holder JE, Ferguson C, Oliveira E, et al. The use of nanoparticles for targeted drug delivery in non-small cell lung cancer. Front Oncol  2023; 13: 1154318.
 [http://dx.doi.org/10.3389/fonc.2023.1154318] [PMID:  36994202]

[88]
Hani U, Gowda BHJ, Haider N, et al. Nanoparticle-based approaches for treatment of hematological malignancies: A comprehensive review. AAPS PharmSciTech  2023; 24(8): 233.
 [http://dx.doi.org/10.1208/s12249-023-02670-0] [PMID:  37973643]

[89]
Merino M, Lozano T, Casares N, et al. Dual activity of PD-L1 targeted Doxorubicin immunoliposomes promoted an enhanced efficacy of the antitumor immune response in melanoma murine model. J Nanobiotechnol  2021; 19(1): 102.
 [http://dx.doi.org/10.1186/s12951-021-00846-z] [PMID:  33849551]

[90]
Gunasekaran K, Vasamsetti BMK, Thangavelu P, et al. Cytotoxic effects of nanoliposomal cisplatin and diallyl disulfide on breast cancer and lung cancer cell lines. Biomedicines  2023; 11(4): 1021.
 [http://dx.doi.org/10.3390/biomedicines11041021] [PMID:  37189638]

[91]
Fantini M, Gianni L, Santelmo C, et al. Lipoplatin treatment in lung and breast cancer. Chemother Res Pract  2011; 2011: 1-7.
 [http://dx.doi.org/10.1155/2011/125192] [PMID:  22295201]

[92]
Tan S, Wang G. Lung cancer targeted therapy: Folate and transferrin dual targeted, glutathione responsive nanocarriers for the delivery of cisplatin. Biomed Pharmacother  2018; 102: 55-63.
 [http://dx.doi.org/10.1016/j.biopha.2018.03.046] [PMID:  29549729]

[93]
Xu B, Zeng M, Zeng J, Feng J, Yu L. Meta-analysis of clinical trials comparing the efficacy and safety of liposomal cisplatin versus conventional nonliposomal cisplatin in nonsmall cell lung cancer (NSCLC) and squamous cell carcinoma of the head and neck (SCCHN). Medicine  2018; 97(46): e13169.
 [http://dx.doi.org/10.1097/MD.0000000000013169] [PMID:  30431590]

[94]
Crous A, Abrahamse H. Photodynamic therapy of lung cancer, where are we? Front Pharmacol  2022; 13: 932098.
 [http://dx.doi.org/10.3389/fphar.2022.932098] [PMID:  36110552]

[95]
Guo S, Wang Y, Miao L, et al. Lipid-coated Cisplatin nanoparticles induce neighboring effect and exhibit enhanced anticancer efficacy. ACS Nano  2013; 7(11): 9896-904.
 [http://dx.doi.org/10.1021/nn403606m] [PMID:  24083505]

[96]
Nishiyama N, Okazaki S, Cabral H, et al. Novel cisplatin-incorporated polymeric micelles can eradicate solid tumors in mice. Cancer Res  2003; 63(24): 8977-83.
 [PMID:  14695216]

[97]
Kesharwani P. Nanotechnology-based targeted drug delivery systems for lung cancer. Academic Press 2019.

[98]
Ram Prasad RP, Rishikesh Pandey RP, Ajit Varma AV, Ishan Barman IB. Polymer-based nanoparticles for drug delivery systems and cancer therapeutics. In: Natural polymers for drug delivery.  UK: CABI Wallingford 2017; pp. 53-70.

[99]
Agarwal A, Asthana A, Gupta U, Jain NK. Tumour and dendrimers: A review on drug delivery aspects. J Pharm Pharmacol  2010; 60(6): 671-88.
 [http://dx.doi.org/10.1211/jpp.60.6.0001] [PMID:  18498702]

[100]
Maya S, Sarmento B, Nair A, Rejinold N, Nair S, Jayakumar R. Smart stimuli sensitive nanogels in cancer drug delivery and imaging: A review. Curr Pharm Des  2013; 19(41): 7203-18.
 [http://dx.doi.org/10.2174/138161281941131219124142] [PMID:  23489200]

[101]
Nag S, Bhatt M, Ghosh S, et al. Drug Delivery for Neurological Disorders Using Nanotechnology, Theranostic Applications of Nanotechnology in Neurological Disorders.  Springer 2024; pp. 135-65.

[102]
Scioli Montoto S, Muraca G, Ruiz ME. Solid lipid nanoparticles for drug delivery: Pharmacological and biopharmaceutical aspects. Front Mol Biosci  2020; 7: 587997.
 [http://dx.doi.org/10.3389/fmolb.2020.587997] [PMID:  33195435]

[103]
Hua S. Lipid-based nano-delivery systems for skin delivery of drugs and bioactives. Front Pharmacol  2015; 6: 219.
 [http://dx.doi.org/10.3389/fphar.2015.00219] [PMID:  26483690]

[104]
Khan MS, Mohapatra S, Gupta V, et al. Potential of lipid-based nanocarriers against two major barriers to drug delivery-skin and blood-brain barrier. Membranes  2023; 13(3): 343.
 [http://dx.doi.org/10.3390/membranes13030343] [PMID:  36984730]

[105]
Movahedi F, Ebrahimi Shahmabadi H, Alavi SE, Koohi Moftakhari Esfahani M. Release modeling and comparison of nanoarchaeosomal, nanoliposomal and pegylated nanoliposomal carriers for paclitaxel. Tumour Biol  2014; 35(9): 8665-72.
 [http://dx.doi.org/10.1007/s13277-014-2125-4] [PMID:  24867099]

[106]
Al Harthi S, Alavi SE, Radwan MA, El Khatib MM, AlSarra IA. Nasal delivery of donepezil HCl-loaded hydrogels for the treatment of Alzheimer’s disease. Sci Rep  2019; 9(1): 9563.
 [http://dx.doi.org/10.1038/s41598-019-46032-y] [PMID:  31266990]

[107]
Gribko A, Künzel J, Wünsch D, et al. Is small smarter? Nanomaterial-based detection and elimination of circulating tumor cells: Current knowledge and perspectives. Int J Nanomedicine  2019; 14: 4187-209.
 [http://dx.doi.org/10.2147/IJN.S198319] [PMID:  31289440]

[108]
Essa ML, El-Kemary MA, Ebrahem Saied EM, Leporatti S, Nemany Hanafy NA. Nano targeted therapies made of lipids and polymers have promising strategy for the treatment of lung cancer. Materials  2020; 13(23): 5397.
 [http://dx.doi.org/10.3390/ma13235397] [PMID:  33261031]

[109]
Pattni BS, Chupin VV, Torchilin VP. New developments in liposomal drug delivery. Chem Rev  2015; 115(19): 10938-66.
 [http://dx.doi.org/10.1021/acs.chemrev.5b00046] [PMID:  26010257]

[110]
White SC, Lorigan P, Margison GP, et al. Phase II study of SPI-77 (sterically stabilised liposomal cisplatin) in advanced non-small-cell lung cancer. Br J Cancer  2006; 95(7): 822-8.
 [http://dx.doi.org/10.1038/sj.bjc.6603345] [PMID:  16969346]

[111]
YN Dou. Thermosensitive Liposome Formulation of Cisplatin for Cancer Treatment. Canada: University of Toronto 2017.

[112]
Boulikas T, Stathopoulos GP, Volakakis N, Vougiouka M. Systemic lipoplatin infusion results in preferential tumor uptake in human studies. Anticancer Res  2005; 25(4): 3031-9.
 [PMID:  16080562]

[113]
Skupin-Mrugalska P. Liposome-based drug delivery for lung cancer, Nanotechnology-based Targeted Drug Delivery Systems for Lung Cancer.  Elsevier 2019; pp. 123-60.

[114]
Xu H, Niu M, Yuan X, Wu K, Liu A. CD44 as a tumor biomarker and therapeutic target. Exp Hematol Oncol  2020; 9(1): 36.
 [http://dx.doi.org/10.1186/s40164-020-00192-0] [PMID:  33303029]

[115]
Stathopoulos GP, Antoniou D, Dimitroulis J, et al. Liposomal cisplatin combined with paclitaxel versus cisplatin and paclitaxel in non-small-cell lung cancer: A randomized phase III multicenter trial. Ann Oncol  2010; 21(11): 2227-32.
 [http://dx.doi.org/10.1093/annonc/mdq234] [PMID:  20439345]

[116]
Boulikas T. Low toxicity and anticancer activity of a novel liposomal cisplatin (Lipoplatin) in mouse xenografts. Oncol Rep  2004; 12(1): 3-12.
 [http://dx.doi.org/10.3892/or.12.1.3] [PMID:  15201951]

[117]
Devarajan P, Tarabishi R, Mishra J, et al. Low renal toxicity of lipoplatin compared to cisplatin in animals. Anticancer Res  2004; 24(4): 2193-200.
 [PMID:  15330160]

[118]
Wu H, Jin H, Wang C, et al. Synergistic cisplatin/doxorubicin combination chemotherapy for multidrug-resistant cancer via polymeric nanogels targeting delivery. ACS Appl Mater Interfaces  2017; 9(11): 9426-36.
 [http://dx.doi.org/10.1021/acsami.6b16844] [PMID:  28247750]

[119]
Krieger ML, Eckstein N, Schneider V, et al. Overcoming cisplatin resistance of ovarian cancer cells by targeted liposomes in vitro. Int J Pharm  2010; 389(1-2): 10-7.
 [http://dx.doi.org/10.1016/j.ijpharm.2009.12.061] [PMID:  20060458]

[120]
Mallick A, More P, Ghosh S, et al. Dual drug conjugated nanoparticle for simultaneous targeting of mitochondria and nucleus in cancer cells. ACS Appl Mater Interfaces  2015; 7(14): 7584-98.
 [http://dx.doi.org/10.1021/am5090226] [PMID:  25811662]

[121]
Yang YT, Shi Y, Jay M, Di Pasqua AJ. Enhanced toxicity of cisplatin with chemosensitizer phenethyl isothiocyanate toward non-small cell lung cancer cells when delivered in liposomal nanoparticles. Chem Res Toxicol  2014; 27(6): 946-8.
 [http://dx.doi.org/10.1021/tx5001128] [PMID:  24836554]

[122]
Wittgen BPH, Kunst PWA, van der Born K, et al. Phase I study of aerosolized SLIT cisplatin in the treatment of patients with carcinoma of the lung. Clin Cancer Res  2007; 13(8): 2414-21.
 [http://dx.doi.org/10.1158/1078-0432.CCR-06-1480] [PMID:  17438100]

[123]
Foote RL, Kasperbauer JL, Okuno SH, et al. A pilot study of high‐dose intraarterial cisplatin chemotherapy with concomitant accelerated radiotherapy for patients with previously untreated T4 and selected patients with T3N0-N3M0 squamous cell carcinoma of the upper aerodigestive tract. Cancer  2005; 103(3): 559-68.
 [http://dx.doi.org/10.1002/cncr.20803] [PMID:  15597408]

[124]
Osaki T, Hanagiri T, Nakanishi R, Yoshino I, Taga S, Yasumoto K. Bronchial arterial infusion is an effective therapeutic modality for centrally located early-stage lung cancer: Results of a pilot study. Chest  1999; 115(5): 1424-8.
 [http://dx.doi.org/10.1378/chest.115.5.1424] [PMID:  10334163]

[125]
Alberts DS, Liu PY, Hannigan EV, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med  1996; 335(26): 1950-5.
 [http://dx.doi.org/10.1056/NEJM199612263352603] [PMID:  8960474]

[126]
Maisch B, Ristić AD, Pankuweit S, Neubauer A, Moll R. Neoplastic pericardial effusion. Efficacy and safety of intrapericardial treatment with cisplatin. Eur Heart J  2002; 23(20): 1625-31.
 [http://dx.doi.org/10.1053/euhj.2002.3328] [PMID:  12323163]

[127]
Markman M, Cleary S, Pfeifle C, Howell SB. Cisplatin administered by the intracavitary route as treatment for malignant mesothelioma. Cancer  1986; 58(1): 18-21.
 [http://dx.doi.org/10.1002/1097-0142(19860701)58:1<18::AID-CNCR2820580105>3.0.CO;2-C] [PMID:  3708543]

[128]
Markman M. Intraperitoneal therapy of ovarian cancer. Oncologist  1996; 1(1-2): 18-21.
 [http://dx.doi.org/10.1634/theoncologist.1-1-18] [PMID:  10387964]

[129]
Rusch VW, Figlin R, Godwin D, Piantadosi S. Intrapleural cisplatin and cytarabine in the management of malignant pleural effusions: A Lung Cancer Study Group trial. J Clin Oncol  1991; 9(2): 313-9.
 [http://dx.doi.org/10.1200/JCO.1991.9.2.313] [PMID:  1988578]

[130]
Duvillard C, Romanet P, Beaudouin N, Cosmidis A, Chauffert B. Phase 2 study of intratumoral cisplatin and epinephrine treatment for locally recurrent head and neck tumors. Ann Otol Rhinol Laryngol  2004; 113(3): 229-33.
 [http://dx.doi.org/10.1177/000348940411300312] [PMID:  15053208]

[131]
Goldberg EP, Hadba AR, Almond BA, Marotta JS. Intratumoral cancer chemotherapy and immunotherapy: Opportunities for nonsystemic preoperative drug delivery. J Pharm Pharmacol  2010; 54(2): 159-80.
 [http://dx.doi.org/10.1211/0022357021778268] [PMID:  11848280]

[132]
Renault-Mahieux M, Vieillard V, Seguin J, et al. Co-encapsulation of fisetin and cisplatin into liposomes for glioma therapy: From formulation to cell evaluation. Pharmaceutics  2021; 13(7): 970.
 [http://dx.doi.org/10.3390/pharmaceutics13070970] [PMID:  34206986]

[133]
Liu Z, Chu W, Sun Q, et al. Micelle-contained and PEGylated hybrid liposomes of combined gemcitabine and cisplatin delivery for enhancing antitumor activity. Int J Pharm  2021; 602: 120619.
 [http://dx.doi.org/10.1016/j.ijpharm.2021.120619] [PMID:  33887396]

[134]
Ocaña-Arakachi K, Martínez-Herculano J, Jurado R, Llaguno-Munive M, Garcia-Lopez P. Pharmacokinetics and anti-tumor efficacy of PEGylated liposomes co-loaded with cisplatin and mifepristone. Pharmaceuticals  2023; 16(10): 1337.
 [http://dx.doi.org/10.3390/ph16101337] [PMID:  37895808]

[135]
Liu J, Wang Z, Li F, Gao J, Wang L, Huang G. Liposomes for systematic delivery of vancomycin hydrochloride to decrease nephrotoxicity: Characterization and evaluation. Asian J Pharm Sci  2015; 10(3): 212-22.

[136]
Hu CMJ, Zhang L. Nanoparticle-based combination therapy toward overcoming drug resistance in cancer. Biochem Pharmacol  2012; 83(8): 1104-11.
 [http://dx.doi.org/10.1016/j.bcp.2012.01.008] [PMID:  22285912]

[137]
Fotsis T, Pepper MS, Aktas E, et al. Flavonoids, dietary-derived inhibitors of cell proliferation and in vitro angiogenesis. Cancer Res  1997; 57(14): 2916-21.
 [PMID:  9230201]

[138]
Bhat TA, Nambiar D, Pal A, Agarwal R, Singh RP. Fisetin inhibits various attributes of angiogenesis in vitro and in vivo implications for angioprevention. Carcinogenesis  2012; 33(2): 385-93.
 [http://dx.doi.org/10.1093/carcin/bgr282] [PMID:  22139440]

[139]
Touil YS, Fellous A, Scherman D, Chabot GG. Flavonoid-induced morphological modifications of endothelial cells through microtubule stabilization. Nutr Cancer  2009; 61(3): 310-21.
 [http://dx.doi.org/10.1080/01635580802521346] [PMID:  19373604]

[140]
Park JH, Jang YJ, Choi YJ, et al. Fisetin inhibits matrix metalloproteinases and reduces tumor cell invasiveness and endothelial cell tube formation. Nutr Cancer  2013; 65(8): 1192-9.
 [http://dx.doi.org/10.1080/01635581.2013.828090] [PMID:  24099040]

[141]
Seguin J, Brullé L, Boyer R, et al. Liposomal encapsulation of the natural flavonoid fisetin improves bioavailability and antitumor efficacy. Int J Pharm  2013; 444(1-2): 146-54.
 [http://dx.doi.org/10.1016/j.ijpharm.2013.01.050] [PMID:  23380621]

[142]
Touil YS, Seguin J, Scherman D, Chabot GG. Improved antiangiogenic and antitumour activity of the combination of the natural flavonoid fisetin and cyclophosphamide in Lewis lung carcinoma-bearing mice. Cancer Chemother Pharmacol  2011; 68(2): 445-55.
 [http://dx.doi.org/10.1007/s00280-010-1505-8] [PMID:  21069336]

[143]
Ansó E, Zuazo A, Irigoyen M, Urdaci MC, Rouzaut A, Martínez-Irujo JJ. Flavonoids inhibit hypoxia-induced vascular endothelial growth factor expression by a HIF-1 independent mechanism. Biochem Pharmacol  2010; 79(11): 1600-9.
 [http://dx.doi.org/10.1016/j.bcp.2010.02.004] [PMID:  20153296]

[144]
Sahu BD, Kalvala AK, Koneru M, et al. Ameliorative effect of fisetin on cisplatin-induced nephrotoxicity in rats via modulation of NF-κB activation and antioxidant defence. PLoS One  2014; 9(9): e105070.
 [http://dx.doi.org/10.1371/journal.pone.0105070] [PMID:  25184746]

[145]
Singhai M, Pandey V, Ashique S, et al. Design and evaluation of SLNs encapsulated curcumin-based topical formulation for the management of cervical cancer. Anticancer Agents Med Chem  2023; 23(16): 1866-79.

[146]
Chi RA, van der Watt P, Wei W, Birrer MJ, Leaner VD. Inhibition of Kpnβ1 mediated nuclear import enhances cisplatin chemosensitivity in cervical cancer. BMC Cancer  2021; 21(1): 106.
 [http://dx.doi.org/10.1186/s12885-021-07819-3] [PMID:  33530952]

[147]
Aktepe OH, Şahin TK, Güner G, Arik Z, Yalçin Ş. Lycopene sensitizes the cervical cancer cells to cisplatin via targeting nuclear factor-kappa B (NF-κB) pathway. Turk J Med Sci  2021; 51(1): 368-74.
 [http://dx.doi.org/10.3906/sag-2005-413] [PMID:  32718121]

[148]
Li H, Zhang Y, Lan X, et al. Halofuginone sensitizes lung cancer organoids to cisplatin via suppressing PI3K/AKT and MAPK signaling pathways. Front Cell Dev Biol  2021; 9: 773048.
 [http://dx.doi.org/10.3389/fcell.2021.773048] [PMID:  34901018]

[149]
Nanayakkara AK, Follit CA, Chen G, Williams NS, Vogel PD, Wise JG. Targeted inhibitors of P-glycoprotein increase chemotherapeutic-induced mortality of multidrug resistant tumor cells. Sci Rep  2018; 8(1): 967.
 [http://dx.doi.org/10.1038/s41598-018-19325-x] [PMID:  29343829]

[150]
Yardley DA. Drug resistance and the role of combination chemotherapy in improving patient outcomes. Int J Breast Cancer  2013; 2013: 1-15.
 [http://dx.doi.org/10.1155/2013/137414] [PMID:  23864953]

[151]
Segovia-Mendoza M, Jurado R, Mir R, Medina LA, Prado-Garcia H, Garcia-Lopez P. Antihormonal agents as a strategy to improve the effect of chemo-radiation in cervical cancer: In vitro and in vivo study. BMC Cancer  2015; 15(1): 21.
 [http://dx.doi.org/10.1186/s12885-015-1016-4] [PMID:  25622528]

[152]
Jurado R, Lopez-Flores A, Alvarez A, García-López P. Cisplatin cytotoxicity is increased by mifepristone in cervical carcinoma: An in vitro and in vivo study. Oncol Rep  2009; 22(5): 1237-45.
 [PMID:  19787245]

[153]
Zamboni WC, Gervais AC, Egorin MJ, et al. Inter- and intratumoral disposition of platinum in solid tumors after administration of cisplatin. Clin Cancer Res  2002; 8(9): 2992-9.
 [PMID:  12231546]

[154]
Ramón-López A, Escudero-Ortiz V, Carbonell V, Pérez-Ruixo JJ, Valenzuela B. Population pharmacokinetics applied to optimising cisplatin doses in cancer patients. Farmacia Hospitalaria: Organo Oficial de Expresion Cientifica de la Sociedad Espanola de Farmacia Hospitalaria  2012; 36(5): 392-402.
 [PMID:  22402361]

[155]
Karasawa T, Sibrian-Vazquez M, Strongin RM, Steyger PS. Identification of cisplatin-binding proteins using agarose conjugates of platinum compounds. PLoS One  2013; 8(6): e66220.
 [http://dx.doi.org/10.1371/journal.pone.0066220] [PMID:  23755301]

[156]
Chang Q, Ornatsky OI, Siddiqui I, Straus R, Baranov VI, Hedley DW. Biodistribution of cisplatin revealed by imaging mass cytometry identifies extensive collagen binding in tumor and normal tissues. Sci Rep  2016; 6(1): 36641.
 [http://dx.doi.org/10.1038/srep36641] [PMID:  27812005]

[157]
Sarkar NN. Mifepristone: Bioavailability, pharmacokinetics and use-effectiveness. Eur J Obstet Gynecol Reprod Biol  2002; 101(2): 113-20.
 [http://dx.doi.org/10.1016/S0301-2115(01)00522-X] [PMID:  11858883]

[158]
Abdel-Hamid NM, Abass SA, Eldomany RA, Abdel-Kareem MA, Zakaria S. Dual regulating of mitochondrial fusion and Timp-3 by leflunomide and diallyl disulfide combination suppresses diethylnitrosamine-induced hepatocellular tumorigenesis in rats. Life Sci  2022; 294: 120369.
 [http://dx.doi.org/10.1016/j.lfs.2022.120369] [PMID:  35120919]

[159]
Abdel-Daim MM, Abdel-Rahman HG, Dessouki AA, et al. Impact of garlic (Allium sativum) oil on cisplatin-induced hepatorenal biochemical and histopathological alterations in rats. Sci Total Environ  2020; 710: 136338.
 [http://dx.doi.org/10.1016/j.scitotenv.2019.136338] [PMID:  31923684]

[160]
Harrington KJ, Lewanski CR, Northcote AD, et al. Phase I-II study of pegylated liposomal cisplatin (SPI-077™) in patients with inoperable head and neck cancer. Ann Oncol  2001; 12(4): 493-6.
 [http://dx.doi.org/10.1023/A:1011199028318] [PMID:  11398881]

[161]
Jung J, Jeong SY, Park SS, et al. A cisplatin-incorporated liposome that targets the epidermal growth factor receptor enhances radiotherapeutic efficacy without nephrotoxicity. Int J Oncol  2015; 46(3): 1268-74.
 [http://dx.doi.org/10.3892/ijo.2014.2806] [PMID:  25544240]

[162]
Ghafoori P, Marks LB, Vujaskovic Z, Kelsey CR. Radiation-induced lung injury. Assessment, management, and prevention. Oncology  2008; 22(1): 37-47.
 [PMID:  18251282]

[163]
Graves EE, Maity A, Le Q-T. The tumor microenvironment in non-small-cell lung cancer, Seminars in radiation oncology.  Elsevier 2010; pp. 156-63.

[164]
Baas P, Belderbos JSA, van den Heuvel M. Chemoradiation therapy in nonsmall cell lung cancer. Curr Opin Oncol  2011; 23(2): 140-9.
 [http://dx.doi.org/10.1097/CCO.0b013e328341eed6] [PMID:  21178617]

[165]
Giaccone G. Twenty-five years of treating advanced NSCLC: What have we achieved? Ann Oncol  2004; 15 (Suppl. 4): iv81-3.
 [http://dx.doi.org/10.1093/annonc/mdh908] [PMID:  15477340]

[166]
Song S, Liu D, Peng J, et al. Peptide ligand-mediated liposome distribution and targeting to EGFR expressing tumor in vivo. Int J Pharm  2008; 363(1-2): 155-61.
 [http://dx.doi.org/10.1016/j.ijpharm.2008.07.012] [PMID:  18692120]

[167]
Jeong SY, Park SJ, Yoon SM, et al. Systemic delivery and preclinical evaluation of Au nanoparticle containing β-lapachone for radiosensitization. J Control Release  2009; 139(3): 239-45.
 [http://dx.doi.org/10.1016/j.jconrel.2009.07.007] [PMID:  19619590]

[168]
van der Meel R, Oliveira S, Altintas I, et al. Tumor-targeted nanobullets: Anti-EGFR nanobody-liposomes loaded with anti-IGF-1R kinase inhibitor for cancer treatment. J Control Release  2012; 159(2): 281-9.
 [http://dx.doi.org/10.1016/j.jconrel.2011.12.027] [PMID:  22227023]

[169]
Liang K, Ang KK, Milas L, Hunter N, Fan Z. The epidermal growth factor receptor mediates radioresistance. Int J Radiat Oncol Biol Phys  2003; 57(1): 246-54.

[170]
Baumann M, Krause M, Dikomey E, et al. EGFR-targeted anti-cancer drugs in radiotherapy: Preclinical evaluation of mechanisms. Radiother Oncol  2007; 83(3): 238-48.
 [http://dx.doi.org/10.1016/j.radonc.2007.04.006] [PMID:  17502118]

[171]
Ansell SM, Harasym TO, Tardi PG, Buchkowsky SS, Bally MB, Cullis PR. Antibody conjugation methods for active targeting of liposomes. Methods Mol Med  2000; 51-68.

[172]
Kolhatkar R, Lote A, Khambhati H. Active tumor targeting of nanomaterials using folic acid, transferrin and integrin receptors. Curr Drug Discov Technol  2011; 8(3): 197-206.
 [http://dx.doi.org/10.2174/157016311796799044] [PMID:  21696360]

[173]
Sharma A, Shambhwani D, Pandey S, et al. Advances in lung cancer treatment using nanomedicines. ACS Omega  2023; 8(1): 10-41.
 [http://dx.doi.org/10.1021/acsomega.2c04078] [PMID:  36643475]

[174]
Vhora I, Khatri N, Desai J, Thakkar HP. Caprylate-conjugated Cisplatin for the development of novel liposomal formulation. AAPS PharmSciTech  2014; 15(4): 845-57.
 [http://dx.doi.org/10.1208/s12249-014-0106-y] [PMID:  24700295]

[175]
Akimaru K, Auzenne E, Akimaru Y, et al. Formulation and antitumor efficacy of liposomal-caprylated-TNF-SAM2. Cytokines Mol Ther  1995; 1(3): 197-210.
 [PMID:  9384676]

[176]
Utsumi T, Hung M-C, Klostergaard J. Preparation and characterization of liposomal-lipophilic tumor necrosis factor. Cancer Res  1991; 51(13): 3362-6.
 [PMID:  2054776]

[177]
Cafaggi S, Russo E, Stefani R, et al. Preparation and evaluation of nanoparticles made of chitosan or N-trimethyl chitosan and a cisplatin-alginate complex. J Control Release  2007; 121(1-2): 110-23.
 [http://dx.doi.org/10.1016/j.jconrel.2007.05.037] [PMID:  17601625]

[178]
Yan X, Gemeinhart RA. Cisplatin delivery from poly(acrylic acid-co-methyl methacrylate) microparticles. J Control Release  2005; 106(1-2): 198-208.
 [http://dx.doi.org/10.1016/j.jconrel.2005.05.005] [PMID:  15979187]

[179]
Shi L, Li Y, Yu T, et al. Predictable resistance and overall survival of gemcitabine/cisplatin by platelet activation index in non-small cell lung cancer. Med Sci Monit  2018; 24: 8655-68.
 [http://dx.doi.org/10.12659/MSM.911125] [PMID:  30498189]

[180]
Dubey RD, Saneja A, Gupta PK, Gupta PN. Recent advances in drug delivery strategies for improved therapeutic efficacy of gemcitabine. Eur J Pharm Sci  2016; 93: 147-62.
 [http://dx.doi.org/10.1016/j.ejps.2016.08.021] [PMID:  27531553]

[181]
Poy D, Ebrahimi Shahemabadi H, Akbarzadeh A, Moradi-Sardareh H, Ebrahimifar M. Carboplatin liposomal nanoparticles: Preparation, characterization, and cytotoxicity effects on lung cancer in vitro environment. Int J Polym Mater  2018; 67(6): 367-70.
 [http://dx.doi.org/10.1080/00914037.2017.1332624]

[182]
Pramanik S, Mohanto S, Manne R, et al. Nanoparticle-based drug delivery system: The magic bullet for the treatment of chronic pulmonary diseases. Mol Pharm  2021; 18(10): 3671-718.
 [http://dx.doi.org/10.1021/acs.molpharmaceut.1c00491] [PMID:  34491754]

[183]
Burhan E, Ruesen C, Ruslami R, et al. Isoniazid, rifampin, and pyrazinamide plasma concentrations in relation to treatment response in Indonesian pulmonary tuberculosis patients. Antimicrob Agents Chemother  2013; 57(8): 3614-9.
 [http://dx.doi.org/10.1128/AAC.02468-12] [PMID:  23689725]

[184]
Daraee H, Etemadi A, Kouhi M, Alimirzalu S, Akbarzadeh A. Application of liposomes in medicine and drug delivery. Artif Cells Nanomed Biotechnol  2016; 44(1): 381-91.
 [http://dx.doi.org/10.3109/21691401.2014.953633] [PMID:  25222036]

[185]
Padhi S, Behera A. Cellular Internalization and Toxicity of Polymeric Nanoparticles. In: Padhi S, Behera A, Lichtfouse E, Eds. Polymeric nanoparticles for the treatment of solid tumors Environmental Chemistry for a Sustainable World.  Cham: Springer 2022; 71: pp. 473-88.

[186]
Ashique S, Guptha PM, Shilpi S, et al. Nanocarrier-mediated delivery for targeting for prostate cancer, Multifunctional Nanocomposites for Targeted Drug Delivery in Cancer Therapy.  Elsevier 2024; pp. 355-92.
 [http://dx.doi.org/10.1016/B978-0-323-95303-0.00008-3]

[187]
Alshammari MK, Almomen EY, Alshahrani KF, et al. Nano-enabled strategies for the treatment of lung cancer: Potential bottlenecks and future perspectives. Biomedicines  2023; 11(2): 473.
 [http://dx.doi.org/10.3390/biomedicines11020473] [PMID:  36831009]

[188]
Padhi S, Behera A. Advanced drug delivery systems in the treatment of ovarian cancer. In: Advanced Drug Delivery Systems in the Management of Cancer.  Elsevier 2021; pp. 127-39.
 [http://dx.doi.org/10.1016/B978-0-323-85503-7.00020-1]

[189]
Bazak R, Houri M, Achy SE, Hussein W, Refaat T. Passive targeting of nanoparticles to cancer: A comprehensive review of the literature. Mol Clin Oncol  2014; 2(6): 904-8.
 [http://dx.doi.org/10.3892/mco.2014.356] [PMID:  25279172]

[190]
Kundu A, Padhi S, Behera A, Hasnain MS, Nayak AK. Tumor targeting strategies by chitosan-based nanocarriers. In: Chitosan in Biomedical Applications.  Elsevier 2022; pp. 163-88.

[191]
Padhi S, Azharuddin M, Behera A, et al. Nanocarriers as delivery tool for COVID-19 drugs. In: Coronavirus Drug Discovery.  Elsevier 2022; pp. 293-332.
 [http://dx.doi.org/10.1016/B978-0-323-95574-4.00018-4]

[192]
Behera A, Padhi S. pH-sensitive polymeric nanoparticles for tumor-targeting doxorubicin delivery: Concept and recent advances. Nanomedicine  2022; 9(3): 487-99.

[193]
Sun T, Zhang YS, Pang B, Hyun DC, Yang M, Xia Y. Engineered nanoparticles for drug delivery in cancer therapy. In: Nanomaterials and Neoplasms.  Jenny Stanford Publishing 2021; pp. 31-142.
 [http://dx.doi.org/10.1201/9780429027819-2]

[194]
Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: The key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul  2001; 41(1): 189-207.
 [http://dx.doi.org/10.1016/S0065-2571(00)00013-3] [PMID:  11384745]

[195]
Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol  2020; 2(12): 751-60.

[196]
Sun S, Wang Y, Gao X, et al. Current perspectives and trends in nanoparticle drug delivery systems in breast cancer: Bibliometric analysis and review. Front Bioeng Biotechnol  2023; 11: 1253048.
 [http://dx.doi.org/10.3389/fbioe.2023.1253048] [PMID:  37771575]

[197]
Gabizon AA, Shmeeda H, Zalipsky S. Pros and cons of the liposome platform in cancer drug targeting. J Liposome Res  2006; 16(3): 175-83.
 [http://dx.doi.org/10.1080/08982100600848769] [PMID:  16952872]

[198]
Drummond DC, Meyer O, Hong K, Kirpotin DB, Papahadjopoulos D. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev  1999; 51(4): 691-743.
 [PMID:  10581328]

[199]
Morse MA, Eklind KI, Hecht SS, et al. Structure-activity relationships for inhibition of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone lung tumorigenesis by arylalkyl isothiocyanates in A/J mice. Cancer Res  1991; 51(7): 1846-50.
 [PMID:  2004368]

[200]
Wang S, Gou J, Wang Y, et al. Synergistic antitumor efficacy mediated by liposomal co-delivery of polymeric micelles of vinorelbine and cisplatin in non-small cell lung cancer. Int J Nanomedicine  2021; 16: 2357-72.
 [http://dx.doi.org/10.2147/IJN.S290263] [PMID:  33790554]

[201]
Mukherjee A, Paul M, Mukherjee S. Recent progress in the theranostics application of nanomedicine in lung cancer. Cancers  2019; 11(5): 597.
 [http://dx.doi.org/10.3390/cancers11050597] [PMID:  31035440]

[202]
Maruyama K. Intracellular targeting delivery of liposomal drugs to solid tumors based on EPR effects. Adv Drug Deliv Rev  2011; 63(3): 161-9.
 [http://dx.doi.org/10.1016/j.addr.2010.09.003] [PMID:  20869415]

[203]
Crommelin DJA, van Hoogevest P, Storm G. The role of liposomes in clinical nanomedicine development. What now? Now what? J Control Release  2020; 318: 256-63.
 [http://dx.doi.org/10.1016/j.jconrel.2019.12.023] [PMID:  31846618]

[204]
Maeda H, Bharate GY, Daruwalla J. Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect. Eur J Pharm Biopharm  2009; 71(3): 409-19.
 [http://dx.doi.org/10.1016/j.ejpb.2008.11.010] [PMID:  19070661]

[205]
Ahmadian S, Sabzichi M, Rashidi M, et al. Sensitization of A-549 lung cancer cells to Cisplatin by Quinacrine-loaded lipidic nanoparticles via suppressing Nrf2 mediated defense mechanism. Naunyn Schmiedebergs Arch Pharmacol  2021; 394(7): 1521-8.
 [http://dx.doi.org/10.1007/s00210-021-02079-1] [PMID:  33735393]

[206]
Klaunig JE. Oxidative stress and cancer. Curr Pharm Des  2019; 24(40): 4771-8.
 [http://dx.doi.org/10.2174/1381612825666190215121712] [PMID:  30767733]

[207]
Sabzichi M, Ramezani M, Mohammadian J, et al. The synergistic impact of quinacrine on cell cycle and anti-invasiveness behaviors of doxorubicin in MDA-MB-231 breast cancer cells. Process Biochem  2019; 81: 175-81.
 [http://dx.doi.org/10.1016/j.procbio.2019.03.007]

[208]
Chen B, Lu Y, Chen Y, Cheng J. The role of Nrf2 in oxidative stress-induced endothelial injuries. J Endocrinol  2015; 225(3): R83-99.
 [http://dx.doi.org/10.1530/JOE-14-0662] [PMID:  25918130]

[209]
Petri S, Körner S, Kiaei M. Nrf2/ARE signaling pathway: Key mediator in oxidative stress and potential therapeutic target in ALS. Neurol Res Int  2012; 2012: 1-7.
 [http://dx.doi.org/10.1155/2012/878030] [PMID:  23050144]

[210]
Ikeda H, Serria MS, Kakizaki I, et al. Activation of mouse Pi-class glutathione S-transferase gene by Nrf2(NF-E2-related factor 2) and androgen. Biochem J  2002; 364(2): 563-70.
 [http://dx.doi.org/10.1042/bj20011756] [PMID:  12023900]

[211]
Tang X, Wang H, Fan L, et al. Luteolin inhibits Nrf2 leading to negative regulation of the Nrf2/ARE pathway and sensitization of human lung carcinoma A549 cells to therapeutic drugs. Free Radic Biol Med  2011; 50(11): 1599-609.
 [http://dx.doi.org/10.1016/j.freeradbiomed.2011.03.008] [PMID:  21402146]

[212]
Maroufi NF, Vahedian V, Mazrakhondi SAM, et al. Sensitization of MDA-MBA231 breast cancer cell to docetaxel by myricetin loaded into biocompatible lipid nanoparticles via sub-G1 cell cycle arrest mechanism. Naunyn Schmiedebergs Arch Pharmacol  2020; 393(1): 1-11.
 [http://dx.doi.org/10.1007/s00210-019-01692-5] [PMID:  31372697]

[213]
Raeisi S, Chavoshi H, Mohammadi M, Ghorbani M, Sabzichi M, Ramezani F. Naringenin-loaded nano-structured lipid carrier fortifies oxaliplatin-dependent apoptosis in HT-29 cell line. Process Biochem  2019; 83: 168-75.
 [http://dx.doi.org/10.1016/j.procbio.2019.05.013]

[214]
Tajmohammadi I, Mohammadian J, Sabzichi M, et al. Identification of Nrf2/STAT3 axis in induction of apoptosis through sub-G1 cell cycle arrest mechanism in HT‐29 colon cancer cells. J Cell Biochem  2019; 120(8): 14035-43.
 [http://dx.doi.org/10.1002/jcb.28678] [PMID:  30993753]

[215]
Garg T, Goyal AK. Liposomes: Targeted and controlled delivery system. Drug Deliv Lett  2014; 4(1): 62-71.
 [http://dx.doi.org/10.2174/22103031113036660015]

[216]
Hajipour H, Hamishehkar H, Nazari Soltan Ahmad S, Barghi S, Maroufi NF, Taheri RA. Improved anticancer effects of epigallocatechin gallate using RGD-containing nanostructured lipid carriers. Artif Cell Nanomed Biotechnol  2018; 46(sup1): 283-92.

[217]
Mohammadian J, Mahmoudi S, Pourmohammad P, et al. Formulation of Stattic as STAT3 inhibitor in nanostructured lipid carriers (NLCs) enhances efficacy of doxorubicin in melanoma cancer cells. Naunyn Schmiedebergs Arch Pharmacol  2020; 393(12): 2315-23.
 [http://dx.doi.org/10.1007/s00210-020-01942-x] [PMID:  32653978]

[218]
Wang Z, Qiao R, Tang N, et al. Active targeting theranostic iron oxide nanoparticles for MRI and magnetic resonance-guided focused ultrasound ablation of lung cancer. Biomaterials  2017; 127: 25-35.
 [http://dx.doi.org/10.1016/j.biomaterials.2017.02.037] [PMID:  28279919]

[219]
Padhi S, Behera A. Nanotechnology based targeting strategies for the delivery of Camptothecin, Sustainable Agriculture Reviews 44: Pharmaceutical Technology for Natural Products Delivery. Impact Nanotechnol  2020; 2: 243-72.

[220]
AlSawaftah N, Pitt WG, Husseini GA. Dual-targeting and stimuli-triggered liposomal drug delivery in cancer treatment. ACS Pharmacol Transl Sci  2021; 4(3): 1028-49.
 [http://dx.doi.org/10.1021/acsptsci.1c00066] [PMID:  34151199]

[221]
Agiba AM, Arreola-Ramírez JL, Carbajal V, Segura-Medina P. Light-responsive and dual-targeting liposomes: From mechanisms to targeting strategies. Molecules  2024; 29(3): 636.
 [http://dx.doi.org/10.3390/molecules29030636] [PMID:  38338380]

[222]
Riaz M, Riaz M, Zhang X, et al. Surface functionalization and targeting strategies of liposomes in solid tumor therapy: A review. Int J Mol Sci  2018; 19(1): 195.
 [http://dx.doi.org/10.3390/ijms19010195] [PMID:  29315231]

[223]
Jain A, Jain SK. Advances in tumor targeted liposomes. Curr Mol Med  2018; 18(1): 44-57.
 [http://dx.doi.org/10.2174/1566524018666180416101522] [PMID:  29663884]

[224]
Ulbrich K, Holá K, Šubr V, Bakandritsos A, Tuček J, Zbořil R. Targeted drug delivery with polymers and magnetic nanoparticles: Covalent and noncovalent approaches, release control, and clinical studies. Chem Rev  2016; 116(9): 5338-431.
 [http://dx.doi.org/10.1021/acs.chemrev.5b00589] [PMID:  27109701]

[225]
Narmani A, Yavari K, Mohammadnejad J. Imaging, biodistribution and in vitro study of smart 99mTc-PAMAM G4 dendrimer as novel nano-complex. Colloids Surf B Biointerfaces  2017; 159: 232-40.
 [http://dx.doi.org/10.1016/j.colsurfb.2017.07.089] [PMID:  28800462]

[226]
Kavand A, Anton N, Vandamme T, Serra CA, Chan-Seng D. Synthesis and functionalization of hyperbranched polymers for targeted drug delivery. J Control Release  2020; 321: 285-311.
 [http://dx.doi.org/10.1016/j.jconrel.2020.02.019] [PMID:  32057990]

[227]
Pakdaman Goli P, Bikhof Torbati M, Parivar K, Akbarzadeh Khiavi A, Yousefi M. Preparation and evaluation of gemcitabin and cisplatin-entrapped Folate-PEGylated liposomes as targeting co-drug delivery system in cancer therapy. J Drug Deliv Sci Technol  2021; 65: 102756.
 [http://dx.doi.org/10.1016/j.jddst.2021.102756]

[228]
Narmani A, Rezvani M, Farhood B, et al. Folic acid functionalized nanoparticles as pharmaceutical carriers in drug delivery systems. Drug Dev Res  2019; 80(4): 404-24.
 [http://dx.doi.org/10.1002/ddr.21545] [PMID:  31140629]

[229]
Yang Y, Zhao Z, Xie C, Zhao Y. Dual-targeting liposome modified by glutamic hexapeptide and folic acid for bone metastatic breast cancer. Chem Phys Lipids  2020; 228: 104882.
 [http://dx.doi.org/10.1016/j.chemphyslip.2020.104882] [PMID:  32017901]

[230]
Valihrach L, Androvic P, Kubista M. Circulating miRNA analysis for cancer diagnostics and therapy. Mol Aspects Med  2020; 72: 100825.
 [http://dx.doi.org/10.1016/j.mam.2019.10.002] [PMID:  31635843]

[231]
Wang P, Zhu M, Zhang D, et al. The relationship between chronic obstructive pulmonary disease and non‐small cell lung cancer in the elderly. Cancer Med  2019; 8(9): 4124-34.
 [http://dx.doi.org/10.1002/cam4.2333] [PMID:  31184445]

[232]
Yu N, Yong S, Kim HK, et al. Identification of tumor suppressor miRNAs by integrative miRNA and mRNA sequencing of matched tumor-normal samples in lung adenocarcinoma. Mol Oncol  2019; 13(6): 1356-68.
 [http://dx.doi.org/10.1002/1878-0261.12478] [PMID:  30913346]

[233]
Pidíkova P, Reis R, Herichova I. miRNA clusters with down-regulated expression in human colorectal cancer and their regulation. Int J Mol Sci  2020; 21(13): 4633.
 [http://dx.doi.org/10.3390/ijms21134633] [PMID:  32610706]

[234]
Ye T, Changyu S, Limeng Z, Yuan P. Clinical significance of miRNA 106a in non-small cell lung cancer patients who received cisplatin combined with gemcitabine chemotherapy. Cancer Biol Med  2018; 15(2): 157-64.
 [http://dx.doi.org/10.20892/j.issn.2095-3941.2017.0182] [PMID:  29951339]

[235]
Deng S, Wu D, Li L, et al. miR-324-3p reverses cisplatin resistance by inducing GPX4-mediated ferroptosis in lung adenocarcinoma cell line A549. Biochem Biophys Res Commun  2021; 549: 54-60.
 [http://dx.doi.org/10.1016/j.bbrc.2021.02.077] [PMID:  33662669]

[236]
Rao C, Miao X, Zhao G, et al. MiR-219a-5p enhances cisplatin sensitivity of human non-small cell lung cancer by targeting FGF9. Biomed Pharmacother  2019; 114: 108662.
 [http://dx.doi.org/10.1016/j.biopha.2019.108662] [PMID:  30999114]

[237]
Ma CC, Wang ZL, Xu T, He ZY, Wei YQ. The approved gene therapy drugs worldwide: From 1998 to 2019. Biotechnol Adv  2020; 40: 107502.
 [http://dx.doi.org/10.1016/j.biotechadv.2019.107502] [PMID:  31887345]

[238]
Chen X, Mangala LS, Rodriguez-Aguayo C, Kong X, Lopez-Berestein G, Sood AK. RNA interference-based therapy and its delivery systems. Cancer Metastasis Rev  2018; 37(1): 107-24.
 [http://dx.doi.org/10.1007/s10555-017-9717-6] [PMID:  29243000]

[239]
Chudal L, Pandey NK, Phan J, Johnson O, Li X, Chen W. Investigation of PPIX-Lipo-MnO2 to enhance photodynamic therapy by improving tumor hypoxia. Mater Sci Eng C  2019; 104: 109979.
 [http://dx.doi.org/10.1016/j.msec.2019.109979] [PMID:  31500001]

[240]
Lu M, Zhao X, Xing H, et al. Comparison of exosome-mimicking liposomes with conventional liposomes for intracellular delivery of siRNA. Int J Pharm  2018; 550(1-2): 100-13.
 [http://dx.doi.org/10.1016/j.ijpharm.2018.08.040] [PMID:  30138707]

[241]
Tian M, Ticer T, Wang Q, et al. Adipose‐derived biogenic nanoparticles for suppression of inflammation. Small  2020; 16(10): 1904064.
 [http://dx.doi.org/10.1002/smll.201904064] [PMID:  32067382]

[242]
Luo C, Miao L, Zhao Y, et al. A novel cationic lipid with intrinsic antitumor activity to facilitate gene therapy of TRAIL DNA. Biomaterials  2016; 102: 239-48.
 [http://dx.doi.org/10.1016/j.biomaterials.2016.06.030] [PMID:  27344367]

[243]
Wimmel A, Schilli M, Kaiser U, et al. Preferential histiotypic expression of CD44-isoforms in human lung cancer. Lung Cancer  1997; 16(2-3): 151-72.
 [http://dx.doi.org/10.1016/S0169-5002(96)00625-3] [PMID:  9152947]

[244]
Pirinen R, Hirvikoski P, Böhm J, et al. Reduced expression of CD44v3 variant isoform is associated with unfavorable outcome in non-small cell lung carcinoma. Hum Pathol  2000; 31(9): 1088-95.
 [http://dx.doi.org/10.1053/hupa.2000.16277] [PMID:  11014576]

[245]
Miyoshi T, Kondo K, Hino N, Uyama T, Monden Y. The expression of the CD44 variant exon 6 is associated with lymph node metastasis in non-small cell lung cancer. Clin Cancer Res  1997; 3(8): 1289-97.
 [PMID:  9815811]

[246]
Jiang Q, Yuan Y, Gong Y, et al. Therapeutic delivery of microRNA-143 by cationic lipoplexes for non-small cell lung cancer treatment in vivo. J Cancer Res Clin Oncol  2019; 145(12): 2951-67.
 [http://dx.doi.org/10.1007/s00432-019-03051-6] [PMID:  31654121]

[247]
Wang L, Niu X, Song Q, et al. A two-step precise targeting nanoplatform for tumor therapy via the alkyl radicals activated by the microenvironment of organelles. J Control Release  2020; 318: 197-209.
 [http://dx.doi.org/10.1016/j.jconrel.2019.10.017] [PMID:  31672622]

[248]
Cai L, Qin X, Xu Z, et al. Comparison of cytotoxicity evaluation of anticancer drugs between real-time cell analysis and CCK-8 method. ACS Omega  2019; 4(7): 12036-42.
 [http://dx.doi.org/10.1021/acsomega.9b01142] [PMID:  31460316]

[249]
Jozefczuk J, Adjaye J. Quantitative real-time PCR-based analysis of gene expression. In: Methods in Enzymology.  Elsevier 2011; pp. 99-109.

[250]
Li M, Jiang M, Chen M, et al. Formulated nano-liposomes for reversal of cisplatin resistance in NSCLC with nucleus-targeting peptide. Nano Res  2023; 16(11): 12864-79.
 [http://dx.doi.org/10.1007/s12274-023-6273-y]

[251]
Jiang M, Fang X, Ma L, et al. A nucleus-targeting peptide antagonist towards EZH2 displays therapeutic efficacy for lung cancer. Int J Pharm  2022; 622: 121894.
 [http://dx.doi.org/10.1016/j.ijpharm.2022.121894] [PMID:  35680109]

[252]
Kim KH, Roberts CWM. Targeting EZH2 in cancer. Nat Med  2016; 22(2): 128-34.
 [http://dx.doi.org/10.1038/nm.4036] [PMID:  26845405]

[253]
Varambally S, Dhanasekaran SM, Zhou M, et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature  2002; 419(6907): 624-9.
 [http://dx.doi.org/10.1038/nature01075] [PMID:  12374981]

[254]
Huqun R, Ishikawa R, Zhang J, et al. Enhancer of zeste homolog 2 is a novel prognostic biomarker in nonsmall cell lung cancer. Cancer  2012; 118(6): 1599-606.
 [http://dx.doi.org/10.1002/cncr.26441] [PMID:  21837672]

[255]
Tu Z, Chen X, Tian T, Chen G, Huang M. Prognostic significance of epigenetic regulatory gene expression in patients with non-small-cell lung cancer. Aging  2021; 13(5): 7397-415.
 [http://dx.doi.org/10.18632/aging.202600] [PMID:  33658396]

[256]
Zheng B, Chen X. Dynamics of histone H3 lysine 27 trimethylation in plant development. Curr Opin Plant Biol  2011; 14(2): 123-9.
 [http://dx.doi.org/10.1016/j.pbi.2011.01.001] [PMID:  21330185]

[257]
Bogliotti YS, Ross PJ. Mechanisms of histone H3 lysine 27 trimethylation remodeling during early mammalian development. Epigenetics  2012; 7(9): 976-81.
 [http://dx.doi.org/10.4161/epi.21615] [PMID:  22895114]

[258]
Wang X, Zhao H, Lv L, Bao L, Wang X, Han S. Prognostic significance of EZH2 expression in non-small cell lung cancer: A meta-analysis. Sci Rep  2016; 6(1): 19239.
 [http://dx.doi.org/10.1038/srep19239] [PMID:  26754405]

[259]
Zang X, Gu J, Zhang J, et al. Exosome-transmitted lncRNA UFC1 promotes non-small-cell lung cancer progression by EZH2-mediated epigenetic silencing of PTEN expression. Cell Death Dis  2020; 11(4): 215.
 [http://dx.doi.org/10.1038/s41419-020-2409-0] [PMID:  32242003]

[260]
Xu C, Hao K, Hu H, et al. Expression of the enhancer of zeste homolog 2 in biopsy specimen predicts chemoresistance and survival in advanced non-small cell lung cancer receiving first-line platinum-based chemotherapy. Lung Cancer  2014; 86(2): 268-73.
 [http://dx.doi.org/10.1016/j.lungcan.2014.09.010] [PMID:  25262426]

[261]
Liu X, Lu X, Zhen F, et al. LINC00665 induces acquired resistance to gefitinib through recruiting EZH2 and activating PI3K/AKT pathway in NSCLC. Mol Ther Nucleic Acids  2019; 16: 155-61.
 [http://dx.doi.org/10.1016/j.omtn.2019.02.010] [PMID:  30889481]

[262]
Wu M, Huang T, Wang J, et al. Antilung cancer effect of ergosterol and cisplatin-loaded liposomes modified with cyclic arginine-glycine-aspartic acid and octa-arginine peptides. Medicine  2018; 97(33): e11916.
 [http://dx.doi.org/10.1097/MD.0000000000011916] [PMID:  30113492]

[263]
Mikada M, Sukhbaatar A, Miura Y, et al. Evaluation of the enhanced permeability and retention effect in the early stages of lymph node metastasis. Cancer Sci  2017; 108(5): 846-52.
 [http://dx.doi.org/10.1111/cas.13206] [PMID:  28211204]

[264]
Saisyo A, Nakamura H, Fang J, et al. pH-sensitive polymeric cisplatin-ion complex with styrene-maleic acid copolymer exhibits tumor-selective drug delivery and antitumor activity as a result of the enhanced permeability and retention effect. Colloids Surf B Biointerfaces  2016; 138: 128-37.
 [http://dx.doi.org/10.1016/j.colsurfb.2015.11.032] [PMID:  26674841]

[265]
Nichols JW, Bae YH. EPR: Evidence and fallacy. J Control Release  2014; 190: 451-64.
 [http://dx.doi.org/10.1016/j.jconrel.2014.03.057] [PMID:  24794900]

[266]
Zhao T, Huang G, Li Y, et al. A transistor-like pH nanoprobe for tumour detection and image-guided surgery. Nat biomed eng  2016; 1(1): 0006.

[267]
Maeda H, Nakamura H, Fang J. The EPR effect for macromolecular drug delivery to solid tumors: Improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo. Adv Drug Deliv Rev  2013; 65(1): 71-9.
 [http://dx.doi.org/10.1016/j.addr.2012.10.002] [PMID:  23088862]

[268]
Liu X, Wu X, Ma Y, et al. Endophytic fungi from mangrove inhibit lung cancer cell growth and angiogenesis in vitro. Oncol Rep  2017; 37(3): 1793-803.
 [http://dx.doi.org/10.3892/or.2017.5366] [PMID:  28098865]

[269]
Majeed S, Abdullah MS, Dash GK, Ansari MT, Nanda A. Biochemical synthesis of silver nanoprticles using filamentous fungi Penicillium decumbens (MTCC-2494) and its efficacy against A-549 lung cancer cell line. Chin J Nat Med  2016; 14(8): 615-20.
 [http://dx.doi.org/10.1016/S1875-5364(16)30072-3] [PMID:  27608951]

[270]
Zhang J, Lai Z, Huang W, et al. Apicidin inhibited proliferation and invasion and induced apoptosis via mitochondrial pathway in non-small cell lung cancer GLC-82 cells. Anti-Canc Agent Med Chem  2017; 17(10): 1374-82.

[271]
Ravi Subbiah MT, Abplanalp W. Ergosterol (major sterol of baker’s and brewer’s yeast extracts) inhibits the growth of human breast cancer cells in vitro and the potential role of its oxidation products. Int J Vitam Nutr Res  2003; 73(1): 19-23.
 [http://dx.doi.org/10.1024/0300-9831.73.1.19] [PMID:  12690907]

[272]
Lin YC, Lee BH, Alagie J, Su CH. Combination treatment of ergosterol followed by amphotericin B induces necrotic cell death in human hepatocellular carcinoma cells. Oncotarget  2017; 8(42): 72727-38.
 [http://dx.doi.org/10.18632/oncotarget.20285] [PMID:  29069821]

[273]
Li S-D, Huang L. Stealth nanoparticles: High density but sheddable PEG is a key for tumor targeting.  Elsevier 2010; pp. 178-81.

[274]
Li X, Zhang J, Chen Y, Liang X, Luo X. The influence of different long-circulating materials on the pharmacokinetics of liposomal vincristine sulfate. Int J Nanomedicine  2016; 11: 4187-97.
 [http://dx.doi.org/10.2147/IJN.S109547] [PMID:  27616886]

[275]
Wehland JD, Lygina AS, Kumar P, et al. Role of the transmembrane domain in SNARE protein mediated membrane fusion: Peptide nucleic acid/peptide model systems. Mol Biosyst  2016; 12(9): 2770-6.
 [http://dx.doi.org/10.1039/C6MB00294C] [PMID:  27345759]

[276]
Zhang L, Wang Y, Gao HL, He Q. The construction of cell-penetrating peptide R8 and pH sensitive cleavable polyethylene glycols co-modified liposomes. Yao Xue Xue Bao  2015; 50(6): 760-6.
 [PMID:  26521450]

[277]
Clark E, Nava B, Caputi M. Tat is a multifunctional viral protein that modulates cellular gene expression and functions. Oncotarget  2017; 8(16): 27569-81.
 [http://dx.doi.org/10.18632/oncotarget.15174] [PMID:  28187438]

[278]
Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med  2005; 352(10): 997-1003.
 [http://dx.doi.org/10.1056/NEJMoa043331] [PMID:  15758010]

[279]
Ying X, Wen H, Lu WL, et al. Dual-targeting daunorubicin liposomes improve the therapeutic efficacy of brain glioma in animals. J Control Release  2010; 141(2): 183-92.
 [http://dx.doi.org/10.1016/j.jconrel.2009.09.020] [PMID:  19799948]

[280]
Charo IF, Nannizzi L, Smith JW, Cheresh DA. The vitronectin receptor alpha v beta 3 binds fibronectin and acts in concert with alpha 5 beta 1 in promoting cellular attachment and spreading on fibronectin. J Cell Biol  1990; 111(6): 2795-800.
 [http://dx.doi.org/10.1083/jcb.111.6.2795] [PMID:  1703545]

[281]
Khalil IA, Kogure K, Futaki S, Harashima H. Octaarginine-modified liposomes: Enhanced cellular uptake and controlled intracellular trafficking. Int J Pharm  2008; 354(1-2): 39-48.
 [http://dx.doi.org/10.1016/j.ijpharm.2007.12.003] [PMID:  18242018]

[282]
Zangabad PS, Mirkiani S, Shahsavari S, et al. Stimulus-responsive liposomes as smart nanoplatforms for drug delivery applications. Nanotechnol Rev  2018; 7(1): 95-122.
 [http://dx.doi.org/10.1515/ntrev-2017-0154] [PMID:  29404233]

[283]
Deshmukh RR, Gawale SV, Bhagwat MK, Ahire PA, Derle ND. A review on: Liposomes. World J Pharm Pharm Sci  2016; 5(3): 506-17.

[284]
Jone A. Liposomes: A short review. J Pharmac Sci Res  2013; 5(9): 181.

[285]
Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov  2005; 4(2): 145-60.
 [http://dx.doi.org/10.1038/nrd1632] [PMID:  15688077]

[286]
Zhu L, Torchilin VP. Stimulus-responsive nanopreparations for tumor targeting. Integr Biol  2013; 5(1): 96-107.
 [http://dx.doi.org/10.1039/c2ib20135f] [PMID:  22869005]

[287]
Fleige E, Quadir MA, Haag R. Stimuli-responsive polymeric nanocarriers for the controlled transport of active compounds: Concepts and applications. Adv Drug Deliv Rev  2012; 64(9): 866-84.
 [http://dx.doi.org/10.1016/j.addr.2012.01.020] [PMID:  22349241]

[288]
Lee Y, Thompson DH. Stimuli‐responsive liposomes for drug delivery. Wiley Interdiscip Rev Nanomed Nanobiotechnol  2017; 9(5): e1450.
 [http://dx.doi.org/10.1002/wnan.1450] [PMID:  28198148]

[289]
Rahim MA, Jan N, Khan S, et al. Recent advancements in stimuli responsive drug delivery platforms for active and passive cancer targeting. Cancers  2021; 13(4): 670.
 [http://dx.doi.org/10.3390/cancers13040670] [PMID:  33562376]

[290]
Shah H, Madni A, Filipczak N, et al. Cisplatin-loaded thermoresponsive liposomes for enhanced anticancer efficacy. J Drug Deliv Sci Technol  2023; 84: 104509.
 [http://dx.doi.org/10.1016/j.jddst.2023.104509]

[291]
Mura S, Nicolas J, Couvreur P. Stimuli-responsive nanocarriers for drug delivery. Nat Mater  2013; 12(11): 991-1003.
 [http://dx.doi.org/10.1038/nmat3776] [PMID:  24150417]

[292]
Chen J, Cheng D, Li J, et al. Influence of lipid composition on the phase transition temperature of liposomes composed of both DPPC and HSPC. Drug Dev Ind Pharm  2013; 39(2): 197-204.
 [http://dx.doi.org/10.3109/03639045.2012.668912] [PMID:  22443684]

[293]
Lindner LH, Hossann M. Factors affecting drug release from liposomes. Curr Opin Drug Discov Devel  2010; 13(1): 111-23.
 [PMID:  20047152]

[294]
Hossann M, Syunyaeva Z, Schmidt R, et al. Proteins and cholesterol lipid vesicles are mediators of drug release from thermosensitive liposomes. J Control Release  2012; 162(2): 400-6.
 [http://dx.doi.org/10.1016/j.jconrel.2012.06.032] [PMID:  22759980]

[295]
Dou YN, Zheng J, Foltz WD, et al. Heat-activated thermosensitive liposomal cisplatin (HTLC) results in effective growth delay of cervical carcinoma in mice. J Control Release  2014; 178: 69-78.
 [http://dx.doi.org/10.1016/j.jconrel.2014.01.009] [PMID:  24440663]

[296]
Dudar TE, Jain RK. Differential response of normal and tumor microcirculation to hyperthermia. Cancer Res  1984; 44(2): 605-12.
 [PMID:  6692365]

[297]
Vujaskovic Z, Poulson JM, Gaskin AA, et al. Temperature-dependent changes in physiologic parameters of spontaneous canine soft tissue sarcomas after combined radiotherapy and hyperthermia treatment. Int J Radiat Oncol Biol Phys  2000; 46(1): 179-85.

[298]
Pang CL. Hyperthermia in oncology. In: Medicine, Dentistry, Nursing & Allied Health.  CRC Press 2015; pp. 1-396.
 [http://dx.doi.org/10.1201/b18487]

[299]
Shen W-C, Louie SG. Immunology for pharmacy students. In: Bioscience, Medicine, Dentistry, Nursing & Allied Health.  Routledge 2019; pp. 1-174.
 [http://dx.doi.org/10.4324/9781482298208]

[300]
Carvalho Júnior AD, Vieira FP, De Melo VJ, et al. Preparation and cytotoxicity of cisplatin-containing liposomes. Braz J Med Biol Res  2007; 40(8): 1149-57.
 [http://dx.doi.org/10.1590/S0100-879X2006005000125] [PMID:  17665053]

[301]
Collins D. pH-sensitive liposomes as tools for cytoplasmic delivery. In: Liposomes as Tools in Basic Research and Industry.  CRC Press 1994; pp. 201-14.

[302]
De Oliveira MC, Boutet V, Fattal E, et al. Improvement of in vivo stability of phosphodiester oligonucleotide using anionic liposomes in mice. Life Sci  2000; 67(13): 1625-37.
 [http://dx.doi.org/10.1016/S0024-3205(00)00745-1] [PMID:  10983856]

[303]
Hospers G, Mulder N, De Jong B, Zijlstra J, De Vries E. Comparison between a human small cell lung carcinoma cell line (GLC4) and an Adriamycin (GLC4-ADR) and a CDDP (GLC4-CDDP) resistant subline. A Preliminary Report, Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy: Proceedings of the Fifth International Symposium on Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy Abano. Padua, ITALY-June 29-July 2, 1987, Springer, 1988, pp. 479-483. 

[304]
Song J, Ren W, Xu T, et al. Reversal of multidrug resistance in human lung cancer cells by delivery of 3-octadecylcarbamoy-lacrylic acid-cisplatin-based liposomes. Drug Des Devel Ther  2017; 11: 441-9.
 [http://dx.doi.org/10.2147/DDDT.S124912] [PMID:  28255230]

[305]
Mamot C, Drummond DC, Hong K, Kirpotin DB, Park JW. Liposome-based approaches to overcome anticancer drug resistance. Drug Resist Updat  2003; 6(5): 271-9.
 [http://dx.doi.org/10.1016/S1368-7646(03)00082-7] [PMID:  14643297]

[306]
Zeng F, Ju RJ, Li XT, Lu WL. Advances in investigations on the mechanism of cancer multidrug resistance and the liposomes-based treatment strategy. J Pharm Investig  2014; 44(7): 493-504.
 [http://dx.doi.org/10.1007/s40005-014-0154-z]

[307]
Casagrande N, De Paoli M, Celegato M, et al. Preclinical evaluation of a new liposomal formulation of cisplatin, lipoplatin, to treat cisplatin-resistant cervical cancer. Gynecol Oncol  2013; 131(3): 744-52.
 [http://dx.doi.org/10.1016/j.ygyno.2013.08.041] [PMID:  24029417]

[308]
Zamboni WC, Gervais AC, Egorin MJ, et al. Systemic and tumor disposition of platinum after administration of cisplatin or STEALTH liposomal-cisplatin formulations (SPI-077 and SPI-077 B103) in a preclinical tumor model of melanoma. Cancer Chemother Pharmacol  2004; 53(4): 329-36.
 [http://dx.doi.org/10.1007/s00280-003-0719-4] [PMID:  14673619]

[309]
Kim ES, Lu C, Khuri FR, et al. A phase II study of STEALTH cisplatin (SPI-77) in patients with advanced non-small cell lung cancer. Lung Cancer  2001; 34(3): 427-32.
 [http://dx.doi.org/10.1016/S0169-5002(01)00278-1] [PMID:  11714540]

[310]
Kieler-Ferguson HM, Chan D, Sockolosky J, et al. Encapsulation, controlled release, and antitumor efficacy of cisplatin delivered in liposomes composed of sterol-modified phospholipids. Eur J Pharm Sci  2017; 103: 85-93.
 [http://dx.doi.org/10.1016/j.ejps.2017.03.003] [PMID:  28263913]

[311]
Parveen S, Arjmand F, Tabassum S. Clinical developments of antitumor polymer therapeutics. RSC Advances  2019; 9(43): 24699-721.
 [http://dx.doi.org/10.1039/C9RA04358F] [PMID:  35528643]

[312]
Hang Z, Cooper MA, Ziora ZM. Platinum-based anticancer drugs encapsulated liposome and polymeric micelle formulation in clinical trials. Biochem Comp  2016; 4(1): 1.

[313]
Stathopoulos G, Boulikas T, Vougiouka M, et al. Pharmacokinetics and adverse reactions of a new liposomal cisplatin (Lipoplatin): Phase I study. Oncol Rep  2005; 13(4): 589-95.
 [http://dx.doi.org/10.3892/or.13.4.589] [PMID:  15756428]

[314]
Ravaioli A, Papi M, Pasquini E, et al. Lipoplatin monotherapy: A phase II trial of second-line treatment of metastatic non-small-cell lung cancer. J Chemother  2009; 21(1): 86-90.
 [http://dx.doi.org/10.1179/joc.2009.21.1.86] [PMID:  19297279]

[315]
Jehn CF, Boulikas T, Kourvetaris A, Possinger K, Lüftner D. Pharmacokinetics of liposomal cisplatin (lipoplatin) in combination with 5-FU in patients with advanced head and neck cancer: First results of a phase III study. Anticancer Res  2007; 27(1A): 471-5.
 [PMID:  17352269]

[316]
Mylonakis N, Athanasiou A, Ziras N, et al. Phase II study of liposomal cisplatin (Lipoplatin™) plus gemcitabine versus cisplatin plus gemcitabine as first line treatment in inoperable (stage IIIB/IV) non-small cell lung cancer. Lung Cancer  2010; 68(2): 240-7.
 [http://dx.doi.org/10.1016/j.lungcan.2009.06.017] [PMID:  19628292]

[317]
Farooq MA, Aquib M, Farooq A, et al. Recent progress in nanotechnology-based novel drug delivery systems in designing of cisplatin for cancer therapy: An overview. Artif Cells Nanomed Biotechnol  2019; 47(1): 1674-92.
 [http://dx.doi.org/10.1080/21691401.2019.1604535] [PMID:  31066300]

[318]
Liposomal-Cisplatin Analogue (L-NDDP) in Treating Patients With Malignant Pleural Mesothelioma. Patent NCT00004033, 2011. Available from: https://clinicaltrials.gov/study/NCT00004033

[319]
Dragovich T, Mendelson D, Kurtin S, Richardson K, Von Hoff D, Hoos A. A Phase 2 trial of the liposomal DACH platinum L-NDDP in patients with therapy-refractory advanced colorectal cancer. Cancer Chemother Pharmacol  2006; 58(6): 759-64.
 [http://dx.doi.org/10.1007/s00280-006-0235-4] [PMID:  16847673]

[320]
de Jonge MJA, Slingerland M, Loos WJ, et al. Early cessation of the clinical development of LiPlaCis, a liposomal cisplatin formulation. Eur J Cancer  2010; 46(16): 3016-21.
 [http://dx.doi.org/10.1016/j.ejca.2010.07.015] [PMID:  20801016]

[321]
Boulikas T. Clinical overview on Lipoplatin™: A successful liposomal formulation of cisplatin. Expert Opin Investig Drugs  2009; 18(8): 1197-218.
 [http://dx.doi.org/10.1517/13543780903114168] [PMID:  19604121]

[322]
Stathopoulos GP, Boulikas T. Lipoplatin formulation review article. J Drug Deliv  2012; 2012: 1-10.
 [http://dx.doi.org/10.1155/2012/581363] [PMID:  21904682]

[323]
Newman MS, Colbern GT, Working PK, Engbers C, Amantea MA. Comparative pharmacokinetics, tissue distribution, and therapeutic effectiveness of cisplatin encapsulated in long-circulating, pegylated liposomes (SPI-077) in tumor-bearing mice. Cancer Chemother Pharmacol  1999; 43(1): 1-7.
 [http://dx.doi.org/10.1007/s002800050855] [PMID:  9923534]

[324]
Cho LC, Dowell JE, Garwood D, Spangler A, Choy H. Prophylactic cranial irradiation with combined modality therapy for patients with locally advanced non-small cell lung cancer. In: Seminars in oncology.  Elsevier 2005; pp. 293-8.

[325]
Canão F, Ferreira H, Neves NM. Liposomal formulations for lung cancer treatment in the last two decades: A systematic review. J Cancer Res Clin Oncol  2022; 148(9): 2375-86.
 [http://dx.doi.org/10.1007/s00432-022-04079-x] [PMID:  35660950]
Rights & Permissions Print Cite
Journal Information
For Authors
For Editors
For Reviewers
Explore Articles
Open Access
Open Access Articles
For Visitors
DOI https://dx.doi.org/10.2174/0113816128304923240704113319	Print ISSN 1381-6128
Publisher Name Bentham Science Publisher	Online ISSN 1873-4286
Current Pharmaceutical Design

Cisplatin-based Liposomal Nanocarriers for Drug Delivery in Lung Cancer Therapy: Recent Progress and Future Outlooks

Abstract Play Pause

Related Journals

Related Books

Abstract
